Additionally, Daiichi Sankyo has partnered with MSD in a $22bn deal to advance ADCs targeting HER3, B7-H3, and CDH6. Each therapy in this pipeline utilises Daiichi Sankyo’s DXd technology. Enhertu and ...
Moderna share price took a blow as CEO Stéphane Bancel outlined a diminished guidance for 2025. Credit: Boston Globe/ Getty Images Moderna lost more than 20% of its value on the stock market as the ...
There are many challenges small and medium sized businesses must overcome in clinical research. Credit: SFIO CRACHO via Shutterstock. The pharma sector is at a crossroads, with major challenges for ...
This month, pharma companies have announced plans to increase the prices of more than 250 branded drugs in the US.
Intra-Cellular’s clinical-stage pipeline is promising, with pipeline agents under development for a wide range of neurological indications.
Eisai and Biogen are one step away from deploying a more convenient version of their jointly developed Alzheimer’s treatment Leqembi (lecanemab-irmb) after the US Food and Drug Administration (FDA) ...
Amgen presented data about its obesity drug at JP Morgan 2025, stating it hopes the once-monthly dosing will make it an attractive therapy.
CEO Albert Bourla expressed modest optimism for Pfizer’s 2025 revenues at JPM 2025, supported by plans to prioritize R&D in oncology and obesity.
After selling its PI3Kα program to Eli Lilly, Scorpion will spinout out a different entity, which will be owned by the biotech’s current shareholders.
In a new webinar, industry experts explore how innovative technology and direct patient communication are transforming medication adherence in the UK.